This company has been marked as potentially delisted and may not be actively trading. IMARA (IMRA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsInsider TradesTrendsBuy This Stock IMRA vs. MENS, GMTX, MOR, ZYME, CALT, MBX, ETHZ, SBTX, AVTE, and BIOAShould you be buying IMARA stock or one of its competitors? The main competitors of IMARA include Jyong Biotech (MENS), Gemini Therapeutics (GMTX), MorphoSys (MOR), Zymeworks (ZYME), Calliditas Therapeutics AB (publ) (CALT), MBX Biosciences (MBX), Flag Ship Acquisition (ETHZ), Silverback Therapeutics (SBTX), Aerovate Therapeutics (AVTE), and BioAge Labs (BIOA). IMARA vs. Its Competitors Jyong Biotech Gemini Therapeutics MorphoSys Zymeworks Calliditas Therapeutics AB (publ) MBX Biosciences Flag Ship Acquisition Silverback Therapeutics Aerovate Therapeutics BioAge Labs IMARA (NASDAQ:IMRA) and Jyong Biotech (NASDAQ:MENS) are both pharmaceutical preparations industry companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings. Which has better earnings and valuation, IMRA or MENS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIMARAN/AN/A$1.49M$0.05767.36Jyong BiotechN/AN/AN/AN/AN/A Does the media favor IMRA or MENS? In the previous week, Jyong Biotech had 3 more articles in the media than IMARA. MarketBeat recorded 4 mentions for Jyong Biotech and 1 mentions for IMARA. Jyong Biotech's average media sentiment score of 0.62 beat IMARA's score of 0.00 indicating that Jyong Biotech is being referred to more favorably in the news media. Company Overall Sentiment IMARA Neutral Jyong Biotech Positive Do insiders & institutionals hold more shares of IMRA or MENS? 49.3% of IMARA shares are held by institutional investors. 37.3% of IMARA shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts rate IMRA or MENS? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IMARA 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is IMRA or MENS more profitable? IMARA's return on equity of 2.12% beat Jyong Biotech's return on equity.Company Net Margins Return on Equity Return on Assets IMARAN/A 2.12% 2.00% Jyong Biotech N/A N/A N/A SummaryIMARA beats Jyong Biotech on 4 of the 7 factors compared between the two stocks. Get IMARA News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRA vs. The Competition Export to ExcelMetricIMARAPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.01B$983.40M$6.12B$10.64BDividend YieldN/A4.84%5.66%4.69%P/E Ratio767.521.2886.1127.75Price / SalesN/A31.01588.17183.92Price / Cash75.2417.6438.3262.20Price / Book11.157.3812.976.80Net Income$1.49M-$7.96M$3.30B$275.97M IMARA Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRAIMARAN/A$38.37+0.2%N/AN/A$1.01BN/A767.5241Insider TradeMENSJyong BiotechN/A$39.69+0.8%N/AN/A$3.02BN/A0.0031Analyst ForecastGMTXGemini TherapeuticsN/A$66.08+1.6%N/A+46.7%$2.86BN/A-66.0830MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730ZYMEZymeworks0.072 of 5 stars$17.08-0.9%N/AN/A$1.28B$122.87M-17.61460News CoverageAnalyst ForecastGap UpCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180MBXMBX BiosciencesN/A$18.04+3.1%$39.88+121.0%N/A$602.81MN/A-3.9536Gap UpETHZFlag Ship AcquisitionN/A$2.45+1.7%N/AN/A$402.85MN/A-0.167News CoverageAnalyst ForecastGap DownSBTXSilverback TherapeuticsN/A$9.72-0.8%N/A-19.0%$350.48MN/A-4.0283High Trading VolumeAVTEAerovate TherapeuticsN/A$8.62+1.7%N/A-87.3%$249.85MN/A-2.8820High Trading VolumeBIOABioAge Labs0.1508 of 5 stars$5.95+1.2%N/AN/A$213.31MN/A0.00N/ANews CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies Jyong Biotech Alternatives Gemini Therapeutics Alternatives MorphoSys Alternatives Zymeworks Alternatives Calliditas Therapeutics AB (publ) Alternatives MBX Biosciences Alternatives Flag Ship Acquisition Alternatives Silverback Therapeutics Alternatives Aerovate Therapeutics Alternatives BioAge Labs Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRA) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredTrump to get REVENGE on the banks??Rumors are swirling that Trump could target the banking system by upending the $5 trillion-a-day SWIFT network...The Oxford Club | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredRefund From 1933: Trump’s Reset May Create Instant WealthTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMARA Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMARA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
